The development of small molecules targeting translesion DNA synthesis could potentially be beneficial for ACC patients with tumors expressing high levels of mRNAs encoding POLβ, POLλ, REV1 and REV3L translesion DNA polymerases. This evidence concerns the gene REV3L and adrenal cortex carcinoma.